NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy.
- Active, not recruiting
- Dec 12, 2007
- 2 min read
Updated: Apr 25, 2022
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy. With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease."
Locations
United States, Arkansas
University of Arkansas for Medical Sciences/Myeloma Institute
ClinicalTrials.gov Identifier: NCT00572169
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy - A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance
First Posted : December 12, 2007
VDTPACE =
Drug: Velcade
Drug: Thalidomide
Drug: Dexamethasone
Drug: Adriamycin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Pawlyn C.
High-risk myeloma: a challenge to define and to determine the optimal treatment.
Lancet Haematol. 2021
Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B.
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Blood. 2013 Jun
Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B.
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.
Blood. 2013 Mar
Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, Van Rhee F, Crowley J, Barlogie B.
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
Haematologica. 2012 Nov
Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B.
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Blood. 2012 Aug